Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | JAK2 | O60674 | 4/20 | 0.42 |
| ▸ | JAK3 | P52333 | 3/20 | 0.42 |
| ▸ | CCNT1 | O60563 | 4/20 | 0.36 |
| ▸ | MAPK1 | P28482 | 4/20 | 0.34 |
| ▸ | SYK | P43405 | 1/20 | 0.34 |
| ▸ | CYP4F2 | P78329 | 2/20 | 0.34 |
| ▸ | CYP4A11 | Q02928 | 2/20 | 0.34 |
| ▸ | CHEK2 | O96017 | 1/20 | 0.34 |
| ▸ | BRD4 | O60885 | 1/20 | 0.33 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.33 |
| ▸ | HDAC3 | O15379 | 1/20 | 0.33 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.33 |
| ▸ | HDAC2 | Q92769 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2377654 | 0.93 | BRD4 (0.37) | JAK2JAK3MAPK1BRD4 | |
| SCHEMBL2377463 | 0.92 | JAK2 (0.41) | JAK2JAK3CCNT1CYP4F2CYP4A11 | |
| SCHEMBL2377685 | 0.90 | JAK2 (0.41) | JAK2JAK3BRD4HDAC3HDAC1 | |
| SCHEMBL2375617 | 0.90 | HTR6 (0.41) | CHEK2 | |
| SCHEMBL2377253 | 0.88 | JAK2 (0.43) | JAK2JAK3CYP4F2CYP4A11KDM4E | |
| SCHEMBL2376949 | 0.88 | JAK2 (0.57) | JAK2JAK3MAPK1 | |
| SCHEMBL2378351 | 0.88 | JAK2 (0.57) | JAK2JAK3MAPK1 | |
| SCHEMBL2376961 | 0.88 | JAK2 (0.57) | JAK2JAK3MAPK1 | |
| SCHEMBL2377327 | 0.88 | BRD4 (0.42) | MAPK1BRD4KDM4E | |
| SCHEMBL2378212 | 0.86 | JAK2 (0.45) | JAK2JAK3MAPK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-102232076-A | Pyrrolopyrazinyl urea kinase inhibitors | HOFFMANN LA ROCHE | 2011-11-02 | — | — | CN | disclosed |
| US-8012974-B2 | Pyrrolopyrazinyl urea kinase inhibitors | ROCHE PALO ALTO LLC (US) | 2011-09-06 | — | — | US | disclosed |
| US-20100144745-A1 | Pyrrolopyrazinyl Urea Kinase Inhibitors | ROCHE PALO ALTO LLC | 2010-06-10 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100144745-A1 | Pyrrolopyrazinyl Urea Kinase Inhibitors | JAK1, JAK3, ULK3 | JAK2 5/4885JAK3 2/4885CCNT1 436/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.